

**SPEAKER:** Now as an interventional cardiologist, it's quite obvious that we do see the very high-risk patients who do have already had their events. They come back for interventions. And so there is definitely a need for additional therapies, especially in those who do not reach their target goal with the statin alone, which should be, at least according to the European guidelines, below 70.

And as you can imagine, there are only actually two statins with which you can actually achieve these low levels. This is atorvastatin and rosuvastatin, but then you have to go up to a high dose. So we see that roughly 35% to 40% of our high-risk patients do not reach this goal, and those are the ones who actually should derive some benefit from further aggressive lipid lowering, for example, by PCSK9 inhibition.